ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 2019 • ACR Convergence 2023

    2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

    Emma Dures1, Bayram Farisogullari2, Eduardo Santos3, Anna Molto4, Caroline Feldthusen5, Claire Harris6, Corinna Elling-Audersch7, Deirdre Conolly8, Elena Elefante9, Fernando Estévez-López10, Ilaria Bini11, Jette Primdahl12, Kirsten Hoeper13, Marie Urban14, Mart van de Laar15, Marta Redondo16, Peter Böhm17, Raj Amarnani18, Rhys Hayward6, Rinie Geenen19, Simona Rednic20, Susanne Pettersson21, Tanja Thomsen22, Till Uhlig23, Valentin Ritschl24 and Pedro Machado25, 1Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, 4HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 5Institute of Neuroscience and Physiology, University of Gothenburg, Department of Health and Rehabilitation, Unit of Physiotherapy, Sahlgrenska Academy, Gothenburg, Sweden, 6Northwick Park Hospital, London North West University Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom, 7Deutsche Rheuma-Liga Bundesverband e.V., Patient Research Partner, Bonn, Germany, 8School of Medicine, Trinity College Dublin, Discipline of Occupational Therapy, Dublin, Ireland, 9Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 10Harvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, 11Anmar, Young, Rome, Italy, Rome, Italy, 12University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 13Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany, 14University Hospitals Bristol, Research Design Service, Bristol, United Kingdom, 15University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, 16Camilo José Cela University, Faculty of Heath Sciences, Madrid, Spain, 17German League against rheumatism, Forschungspartner, Bonn, Germany, 18Barts Health NHS Trust, Barts Health Rheumatology Service, London, United Kingdom, 19Utrecht University, Vorstenbosch, Netherlands, 20Prof Dr Simona Rednic, Cluj, Romania, 21Karolinska Institute, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 22University of Copenhagen, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases VRR, Rigshospitalet, Copenhagen, Denmark, 23Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 24Medical University of Vienna, Vienna, Austria, 25Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom

    Background/Purpose: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognized as one of the most challenging symptoms to manage (1).…
  • Abstract Number: 0443 • ACR Convergence 2023

    The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis

    Anna Fishbein1, Mai Anh Nguyen2, Ohn Chow3, Tiago Matos4, Caroline Dreis5, Hong Zhang3, Marion Poirel6, Johann Gassenhuber5, Michael Dufault3, Wagner Frank-Dietrich7, Laurent Perrin8, Markus Rehberg5, Markus Kohlmann5 and Nassr Nassr5, 1Sanofi, Bridgewater, NJ, 2Sanofi, Berlin, Germany, 3Sanofi, Cambridge, MA, 4Sanofi, Amsterdam, Netherlands, 5Sanofi, Frankfurt, Germany, 6IT&M Stats, Neuilly-sur-Seine, France, 7Charité Research Organisation, Berlin, Germany, 8Sanofi, Montpellier, France

    Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…
  • Abstract Number: 2142 • ACR Convergence 2023

    Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors

    W. Cliff Rutter, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, Will Cavers, Chen Liu, Rashmi Grover, Lucia Feczko and Kjel Johnson, CVS Health, Woonsocket, RI

    Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…
  • Abstract Number: 0525 • ACR Convergence 2023

    Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

    Marina Nighat Magrey1, Marleen van de Sande2, Maxime Breban3, Filip Van den Bosch4, Carmen Fleurinck5, Ute Massow6, Natasha De Peyrecave7, Thomas Vaux8, Xenofon Baraliakos9 and Helena Marzo-Ortega10, 1Case Western Reserve University, University Hospitals, Cleveland, OH, 2Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 3CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, 4Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5UCB Pharma, Oosterzele, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Slough, United Kingdom, 9Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 10NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
  • Abstract Number: 2507 • ACR Convergence 2023

    ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…
  • Abstract Number: 0542 • ACR Convergence 2023

    Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study

    Irini Flouri1, Argyro Repa2, Nestor Avgoustidis2, Sofia Pitsigavdaki3, Katerina Pateromichelaki2, Maria Terizaki2, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

    Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…
  • Abstract Number: 2541 • ACR Convergence 2023

    Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

    Joshua Baker1, James O'Dell2, Bryant England2, Jon Giles3, Jefferey Newcomb4, Michael George1, Geoffrey Thiele2, Larry Moreland5, S. Louis Bridges6, Jeffrey R Curtis7 and Ted R Mikuls8, 1University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Columbia University, New York, NY, 4University of Nebraska, Omaha, NE, 5University of Colorado, Denver, CO, 6Hospital for Special Surgery, New York, NY, 7Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 8Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
  • Abstract Number: 0834 • ACR Convergence 2023

    Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Christina Gulla1, Tara Lozy2, Daniel Choi3, Ginger Janow4 and For The CARRA Registry Investgators5, 1HUMC pediatrics residency, Hackensack, NJ, 2Ccenter for Discovery and Innovation, Hackensack, NJ, 3Hackensack Meridian School of Medicine, Nutley, NJ, 4Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Glen Rock, NJ, 5CARRA, Inc, Washington, DC

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Tumor necrosis factor inhibitors (TNFi) have demonstrated efficacy and safety in older…
  • Abstract Number: 0927 • ACR Convergence 2023

    A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus

    Robert Clancy1, Caroline Izmirly1, Miranda Marion2, Nicola Fraser1, Joel Guthridge3, Timothy Howard2, Peter Izmirly4, Mala Masson5, Jill Buyon1, Judith James3 and Carl Langefeld6, 1NYU Grossman School of Medicine, New York, NY, 2Wake Forest University, Winston-Salem, NC, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4New York University School of Medicine, New York, NY, 5New York University, New York, NY, 6Wake Forest University School of Medicine, Winston-Salem, NC

    Background/Purpose: Mothers of children with neonatal lupus (NL) are often clinically asymptomatic or have insufficient criteria for a formal rheumatologic diagnosis, despite having high titers…
  • Abstract Number: 0979 • ACR Convergence 2023

    Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases

    Leah K. Flatman1, Sasha Bernatsky2, Isabelle Malhamé3, Yvan St. Pierre2, Olga Basso1, Anick Bérard4 and Evelyne Vinet5, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4University of Montreal, Montreal, QC, Canada, 5McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
  • Abstract Number: 1073 • ACR Convergence 2023

    Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

    Maximilian Casey1, Sonia Pannu2, Saffia Bajwa3, Ali Duarte-Garcia4 and Mike Putman5, 1Medical College of Wisconsin, Milwaukee, WI, 2University School of Milwaukee, River Hills, WI, 3Medical College of Wisconsin, Wauwatosa, WI, 4Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Inflammatory and demyelinating central nervous system (CNS) adverse events have been observed among new users of tumor necrosis factor (TNF) inhibitors. No studies to…
  • Abstract Number: 1333 • ACR Convergence 2023

    Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset

    YOSHIHIKO HOSHIDA1, Atsuko Tsujii2, SHIRO OHSHIMA3, YUKIHIKO SAEKI3, MASATO YAGITA4, TOMOYA MIYAMURA5, Masao Katayama6, TOMONORI KAWASAKI7, YASUSHI HIRAMATSU8, Hisaji Oshima9, TOSHIHIKO MURAYAMA10, SHINJI HIGA11, KAZUYA KURAOKA12, FUMINORI HIRANO13, KENJI ICHIKAWA14, MITSUTOSHI KUROSAWA15, HIROAKI SUZUKI15, NORIYUKI CHIBA16, TAKAO SUGIYAMA17, YUKO MINAMI18, HITOSHI NIINO19, ATSUSHI IHATA20, IKUO SAITO21, AKIKO MITSUO22, TOSHITAKA MAEJIMA23, ATSUHIRO KAWASHIMA24, HIROSHI TSUTANI25, KOICHIRO TAKAHI26, TAKAHIKO KASAI27, YOKO SHINNO28, YOSHIRO TACHIYAMA29, NORIHIRO TERAMOTO30, KENICHI TAGUCHI31, SHINJI NAITO32, SHIGERU YOSHIZAWA33, MASAHIRO ITO34, YASUO SUENAGA35, Shunsuke Mori36, SHOICHI NAGAKURA37, NORIE YOSHIKAWA38, MITSUHARU NOMOTO39, ATSUHISA UEDA40, SHOUHEI NAGAOKA41, YUKIO TSUURA42, KEIGO SETOGUCHI43, SHOJI SUGII44, Asami Abe45, TOSHIAKI SUGAYA46, HIROYUKI SUGAHARA47, MASAHIRO KOSETO48, YASUO KUNUGIZA2, NORISHIGE IIZUKA3, RYOSUKE YOSHIHARA4, HIROKI YABE5, TOMOAKI FUJISAKI6, EIICHI MORII7, MORISHIGE TAKESHITA8, MASAKAZU SATO9, KAZUYOSHI SAITO10, Kiyoshi Matsui11, YASUHIKO TOMITA12, HIROSHI FURUKAWA13 and Shigeto Tohma14, 1National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, 2Osaka Minami Medical Center, Kawachinagano City, Japan, 3National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, 4Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, 5NHO Kyushu Medical Center, Fukuoka, Japan, 6National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, 7NHO Nagoya Medical Center, Nagoya, Japan, 8Japanese Red Cross Society Himeji Hospital, Himeji, Japan, 9National Tokyo Medical Center, Tokyo, Japan, 10NHO Kumamoto Medical Center, Kumamoto, Japan, 11Daini Osaka Police Hospital, Osaka, Japan, 12NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, 13NHO Asahikawa Medical Center, Asahikawa, Japan, 14Nissei hospital, Sapporo, Japan, 15NHO Hokkaido Cancer Center, Sapporo, Japan, 16NHO Morioka Medical Center, Morioka, Japan, 17NHO Shimoshizu Hospital, Yotsukaido, Japan, 18NHO Ibarakihigashi Hospital, Ibaraki, Japan, 19NHO Yokohama Medical Center, Yokohama, Japan, 20National Hospital Organization Yokohama Medical Center, Yokohama, Japan, 21NHO Sagamihara Hospital, Sagamihara, Japan, 22NHO Disaster Medical Center, Tachikawa, Japan, 23NHO Shinshu Ueda Medical Center, Ueda, Japan, 24NHO Kanazawa Medical Center, Kanazawa, Japan, 25NHO Awara Hospital, Awara, Japan, 26NHO Osaka Toneyama Medical Center, Toyonaka, Japan, 27Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, 28NHO Okayama Medical Center, Okayama, Japan, 29NHO Hiroshima Nishi Medical Center, Otake, Japan, 30NHO Shikoku Cancer Center, Matsuyama, Japan, 31NHO Kyushu Cancer Center, Fukuoka, Japan, 32NHO Ureshino Medical Center, Ureshino, Japan, 33NHO Fukuoka Hospital, Fukuoka, Japan, 34NHO Nagasaki Medical Center, Omura, Japan, 35NHO Beppu Medical Center, Beppu, Japan, 36NHO Kumamoto Saishun Medical Center, Koshi, Japan, 37NHO Kumamoto Minami Hospital, Uki, Japan, 38NHO Miyakonojo Medical Center, Miyakonojo, Japan, 39NHO Kagoshima Medical Center, Kagoshima, Japan, 40Yokohama City University Medical Center, Yokohama, Japan, 41Yokohama Minami Kyosai Hospital, Yokohama, Japan, 42Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, 43Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 44Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, 45Niigata Rheumatic Center, Shibata, Japan, 46Fuchu Hospital, Izumi, Japan, 47Sumitomo Hospital, Osaka, Japan, 48Nippon Life Hospital, Osaka, Japan, 49JCHO Hoshigaoka Medical Center, Hirakata, Japan, 50Kishiwada City Hospital, Kishiwada, Japan, 51Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, 52Ako Central Hospital, Ako, Japan, 53Matsuyama Red Cross Hospital, Matsuyama, Japan, 54Osaka University, Suita, Japan, 55Fukuoka University, Fukuoka, Japan, 56Kurashiki University of Science and the Arts, Kurashiki, Japan, 57University of Occupational and Environmental Health, Kitakyushu, Japan, 58Hyogo Medical University, Nishinomiya, Japan, 59International University of Health and Welfare, Otawara City, Japan, 60NHO Tokyo National Hospital, Kiyose, Japan, 61NHO Tokyo National Hospital, Dallas, TX

    Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
  • Abstract Number: 1425 • ACR Convergence 2023

    Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis

    Dafna Gladman1, Peter Nash2, Philip J. Mease3, Oliver FitzGerald4, Karim R. Masri5, Stephanie Duench6 and Mary Jane Cadatal7, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2School of Medicine, Griffith University, Brisbane, Australia, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Pfizer Inc., Collegeville, PA, 6Pfizer Inc., New York, NY, 7Pfizer Inc., Manila, Philippines

    Background/Purpose: Patients (pts) with PsA and an inadequate response (IR) to conventional synthetic DMARDs are routinely treated with TNF inhibitors (TNFi).1,2 Intolerance/IR to TNFi may…
  • Abstract Number: 1428 • ACR Convergence 2023

    Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)

    Laure Gossec1, Xenofon Baraliakos2, James Galloway3, Lars Erik4, Vilija Oke5, Petros Sfikakis6, Emmanouil Rampakakis7, Mohamed Sharaf8, Frederic Lavie9 and Iain McInnes10, 1Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3King's College London, London, United Kingdom, 4Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 5Karolinska Institutet, Stockholm, Sweden, 6National Kapodistrian University of Athens Medical School, Athens, Greece, 7JSS Medical Research, Saint-Laurent, QC, Canada, 8Immunology, Janssen MEA, Dubai, United Arab Emirates, 9The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 10University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology